MTD vs. REGN: Mettler-Toledo vs. Regeneron Pharmaceuticals Stock Comparison

Company Profile

Mettler-Toledo (MTD) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while REGN is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Regeneron Pharmaceuticals (REGN) earns 14.95% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

Both Mettler-Toledo (MTD) at 22.25% and Regeneron Pharmaceuticals (REGN) at 28.51% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Mettler-Toledo (MTD) at 28.70% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Mettler-Toledo (MTD) at 3.98% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Mettler-Toledo (MTD) at 3.88% and Regeneron Pharmaceuticals (REGN) at 8.19% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

Regeneron Pharmaceuticals (REGN) at 0.08 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Mettler-Toledo (MTD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

Mettler-Toledo (MTD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Mettler-Toledo (MTD) at 37.38 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Mettler-Toledo (MTD) at 8.16 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Regeneron Pharmaceuticals (REGN) at 2.71 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

Valuation Metrics